key: cord-0748463-xm6j3wle authors: Gordon, Siamon title: Remembering Metchnikoff in the time of COVID‐19 date: 2021-02-25 journal: J Leukoc Biol DOI: 10.1002/jlb.4ce0520-304rrr sha: d96cf23c0fd0a2e7373dbcd40983725b273c9512 doc_id: 748463 cord_uid: xm6j3wle xx The current year marks the 175th birthday of Elie Metchnikoff (1845 Metchnikoff ( -1916 ) (See Fig. 1) , grandfather of the M , its phagocytic capacity and role in natural resistance to microbes. 1 His research extended beyond F I G U R E 1 Photograph of Elie Metchnikoff (1845 Metchnikoff ( -1916 , considered the grandfather of macrophages the defense of the host to pathogens, to include his obsession with the resident bacteria of the gut, the microbiome, and the process of aging, both cofactors in the host-pathogen interaction that determines the outcome after infection by COVID-19. It therefore seemed of more than historic interest to trace the relevance of his ideas to the present pandemic. We have selected a review he wrote in 1909 on the microbiome and its possible therapeutic potential, 2 translated here into English, to assess its contemporary significance. At the same time, we explore aspects of host susceptibility to infections such as COVID-19, which perfectly illustrates the complex interplay between the host and pathogen, as evident from historic and contemporary studies on M s. René Dubos (1901 -1982 9 Legionella, whereas Cohn turned to tuberculosis, leprosy and eventually HIV, as well as Trypanosoma Cruzi, to define the phagosomal interactions with lysosomes. 18 Studies in the Hirsch-Cohn laboratory showed that myeloid leukocytes are not only "specialized professional" phagocytes, 19 but also potent secretory cells. 20 The mechanisms of opsonic phagocytosis, endocytosis and viral entry were explored, among other topics. 21 Given this background, it was logical to apply the experimental legacy of Metchnikoff and Dubos, to the immunopathogenesis of COVID-19. 25 It would not have been possible to invent a disease to illustrate better the concepts outlined above. From the host viewpoint, the infection can vary from asymptomatic to mild clinical disease and recovery, or in a subset of patients, progression to a life threatening, hyperinflammatory syndrome. 26 There is circumstantial evidence that M s contribute to several of the comorbidities that increase the risk of severe infection, including aging and metabolic predisposing disorders such as obesity, diabetes and atherosclerosis. There is little evidence at present that tissue M s express the ACE2 receptor required for direct infection. They are the major cells implicated in clearance of dying epithelial and endothelial cells and tissue debris by a range of scavenger and opsonic receptors. As sources of antiviral interferons, pro-and anti-inflammatory cytokines, chemokines, pro and anti-coagulants, and low molecular weight radicals and metabolites, they contribute to immune activation, inflammation, and resolution of infection. The basis of the dysregulated hyperinflammatory syndrome, mainly attributed to myeloid rather than lymphoid cells, is not yet clear, but potential clues have begun to emerge. One is an ineffective interferon response, 27 another the role of oxidized membrane-derived lipids, reported to activate inflammasome and caspase-mediated IL-1 beta release by viable M s. 28 Tyrosine-phosphorylated receptors such as AXL play a role in recognition of phosphatidyl serine expression by infected cells, as well as promoting the entry of COVID 29 as co-receptors to ACE2. 30 Arachidonate metabolites such as maresins and resolvins, 31 Finally, the widespread tissue distribution of M s and their migration through blood and lymph, provide a Trojan horse mechanism, 35 independent of ACE2 expression, for monocytes and M s to disseminate virus systemically to all major organs of the body, including lungs, spleen, gut, heart, brain, liver, and kidney, as well as bone marrow and lymph nodes. These circulating and migrating mononuclear phagocytes express an array of C-type lectins such as CD169(Siglec-1) that could serve such a function. 36 We have emphasized cellular and host properties that place M s at the center of the host-pathogen interaction, and have considered selected aspects of COVID-19 pathogenesis that may apply to infectious diseases in general. The prescience and lives of pioneers such as Bacteriotherapie intestinale inMedicaments Microbiens in Bacteriotherapie, Vaccination Serotherapie My stay in Messina (Memories of the past Editions en Langues Etrangères The phagocyte, Metchnikoff, and the foundation of immunology Lectures on the Comparative Pathology of Inflammation Immunity in Infective Diseases. Cambridge The Nobel lectures in immunology. The Nobel prize for physiology or medicine, 1908, awarded to Elie Metchnikoff & Paul Ehrlich "in recognition of their work on immunity The Prolongation of Life: Optimistic Studies. London: William Heineman Launching the antibiotic era-personal accounts of the discovery and use of the first antibiotics The micro-environment of inflammation or Metchnikoff revisited General Pathology. 4th. Philadelphia and London: WB Saunders Co Lymphocytes In Florey HW, op cit Cellular immunity Mobilization of defensive cells in inflammatory tissue Immunity to infectious diseases: review of some concepts of Metchnikoff 1926-1993:an appreciation of the physician-scientist:the macrophage in cell biology and resistance to infection Professional and non-professional phagocytes: an introduction Physiological roles of macrophages An appreciation of Ralph Marvin Steinman(1943-2011) Pluddemann A Tissue macrophages: heterogeneity and functions Molecular mediators of macrophage fusion Monocyte activation in systemic COVID-19 infection:assay and rationale Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Endogenous oxidized phospholipids reprogram cellular metabolism and boost hyperinflammation Phosphatidylserine receptors: enhancers of enveloped virus entry and infection COVID-19: a New Virus, but a Familiar Receptor and Cytokine Release Syndrome Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19. Cancer Metastasis Rev Aging immunity may exacerbate COVID-19. Science Drivers of age-related inflammation and strategies for healthspan extension Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction Macrophages: a Trojan horse in COVID-19? Longitudinal immune profiling reveals distinct features of COVID-19 pathogenesis Immunity: How Elie Metchnikoff Changed the Course of Modern Medicine Falling awake 2016 Cape Poetry